This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amicus Therapeutics' CEO Hosts GSK Expanded Fabry Collaboration Call (Transcript)

Amicus Therapeutics, Inc.

Amicus and GSK Expanded Fabry Collaboration Call

July 17, 2012 05:00 pm ET


John Crowley – Chairman & Chief Executive Officer

David Lockhart – Chief Scientific Officer

Pol Boudes, MD – Chief Medical Officer

Chip Baird – Chief Financial Officer

Bradley Campbell – Chief Business Officer

Sara Pellegrino – Associate Director, Investor Relations


Ritu Baral – Canaccord Genuity

Anupam Rama – JP Morgan

Kim Lee – ThinkEquity

Bill Tanner – Lazard Capital Markets



Good day, ladies and gentlemen, and welcome to your Amicus and GSK Expanded Fabry Collaboration Call. (Operator instructions.) As a reminder, today’s conference is being recorded. And now I would like to introduce your host for today, Sara Pellegrino.

Sara Pellegrino

Good afternoon and thank you for joining our conference call to discuss the expansion of our collaboration with GSK to develop and commercialize co-formulations of migalastat for Fabry disease. Speaking on today’s call we have John Crowley, our Chairman and Chief Executive Officer; Bradley Campbell, our Chief Business Officer; and David Lockhart, our Chief Scientific Officer. They are joined by Chip Baird, our Chief Financial Officer, and Pol Boudes, our Chief Medical Officer, who are available to participate in the Q&A Session.

As a reminder, the presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business, operations and financial conditions of Amicus including but not limited to preclinical and clinical development of Amicus candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products, the projected cash position for the company and business development and other transactional activities. Words such as but not limited to “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “would,” “should,” and “could,” and similar expressions and words identify forward-looking statements.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs